+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using PTPRD mouse mAb (green) and negative control (red).    

  
  

The protein tyrosine phosphatase receptor type D (PTPRD) is a member of the type II receptor-like protein tyrosine phosphatase family, primarily expressed in the nervous system and implicated in neuronal development, synaptic plasticity, and cell signaling regulation. Structurally, PTPRD features a large extracellular domain containing fibronectin type III repeats, a transmembrane region, and two intracellular phosphatase domains. It interacts with ligands like SLITRK proteins to mediate cell-cell adhesion and axon guidance. Dysregulation of PTPRD is associated with neuropsychiatric disorders (e.g., autism, addiction), neurodegenerative diseases, and cancers, where it often acts as a tumor suppressor. Somatic mutations or epigenetic silencing of PTPRD are observed in glioblastoma, lung cancer, and melanoma, frequently linked to hyperactivation of STAT3 signaling.

PTPRD antibodies are critical tools for studying its expression, localization, and function. They are widely used in Western blotting, immunohistochemistry, and immunoprecipitation to assess protein levels in tissues or cell lines, detect pathogenic mutations, or explore interactions with signaling partners like STAT3 or Trk receptors. Commercial antibodies often target specific epitopes within its phosphatase domains or extracellular regions. However, variability in antibody specificity requires careful validation, particularly given PTPRD’s structural similarity to other PTP receptors. Research applications span neurobiology (e.g., synapse formation) and oncology (e.g., tumor suppressor mechanisms), making these antibodies vital for elucidating PTPRD’s role in health and disease.